Lineage Cell Therapeutics, Inc. (LCTX) financial statements and ratios from SEC XBRL: revenue $14.56M (TTM), net margin -436.5%, revenue growth -61.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $14.56M |
| Net Margin | -436.5% |
| Revenue Growth (YoY) | -61.3% |
| EPS Growth (YoY) | -107.7% |
| FCF Growth (YoY) | 32.4% |
| Price / Book | 4.57 |
| Price / Sales | 20.88 |
| FCF Yield | -8.9% |
| Altman Z-Score | -3.91 (distress) |
| Sector P/E (Healthcare) | 21.7 |
LCTX overview · LCTX earnings · LCTX KPIs · LCTX investor relations · LCTX ownership · LCTX peers · LCTX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.